AbbVie Inc. filed a patent infringement lawsuit Wednesday against German rival Boehringer Ingelheim Pharmaceuticals Inc., the second case in Delaware that seeks to block sales of a less-expensive biosimilar version of Humira, AbbVie’s top-selling drug.
The suit accuses Boehringer of infringing dozens of AbbVie’s patents in a bid to bring its copy of the anti-inflammatory treatment to market under a federal law that provides for expedited regulatory approval of drugs that are exceptionally similar to innovative products already being sold in the United States.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
